Article Sidebar
Published:
Jun 17, 2022DOI:
10.4314/tjpr.v21i5.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Glycitin exerts anticancer effect on human lung cancer cells through induction of apoptosis, cell cycle arrest, and inhibition of PI3K/AKT signal pathway
Abstract
Purpose: To determine the effect of glycitin on PI3K/AKT signaling, migration, invasion, apoptosis, and cell cycle in A549 lung cancer cells.
Methods: 3-[4,5-Dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) and clonogenic assays were used to determine the proliferation and colony generation potency of A549 cells, respectively, after treatment with glycitin (0 - 120 μM). Apoptosis in A549 cells was measured using DAPI and Annexin V/PI-FITC assays. Cell cycle arrest was assessed byflow cytometry, while the effect of glycitin on migration and invasion of A549 cells was determined by Transwell assay. The effect of glycitin on expressions of proteins associated with PI3K/AKT signaling in A549 cells was measured using western blotting.
Results: Glycitin significantly inhibited the proliferation and colony generation potential of A549 cells (p < 0.05). The antiproliferative effects of glycitin on A549 cells were mediated through stimulation of apoptosis and cell cycle arrest at G0/G1-phase. The compound also distorted normal cellular morphology by causing membrane damage and nuclear fragmentation. The proportion of cells in the G0/G1-phase increased after glycitin treatment, when compared to the other two phases, demonstrating cell cycle arrest (p < 0.05). Glycitin suppressed the migration and invasion of A549 cells. However, Western blotting results showed that glycitin down-regulated the expressions of PI3K/AKT signaling proteins in A549 cells (p < 0.05).
Conclusion: Glycitin produced significant anticancer effect on A549 cells via enhanced apoptosis, induction of cell cycle arrest, and inhibition of PI3K/AKT signalling. Moreover, it suppressed the migration and invasion of A549 cells. Therefore, glycitin is a potential lead molecule for the development of a therapeutic agent for invasive lung cancer.
